EU/3/13/1171: Orphan designation for the prevention of rejection following solid organ transplantation
Autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+
Table of contents
Overview
On 7 October 2013, orphan designation (EU/3/13/1171) was granted by the European Commission to iReg Medical AB, Sweden, for autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+ for the prevention of rejection following solid organ transplantation.
Key facts
Active substance |
Autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+
|
Intended use |
Prevention of rejection following solid organ transplantation
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/13/1171
|
Date of designation |
08/10/2013
|
Sponsor |
IReg Medical AB
Tallmov 2 A 756 45 Uppsala Sweden Telephone: +46 18 30 22 98 E-mail: info@iregmedical.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: